Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GE Healthcare Launches Modular Biopharmaceutical Factory, KUBio

Published: Tuesday, January 15, 2013
Last Updated: Tuesday, January 15, 2013
Bookmark and Share
Innovative approach will save biopharmaceutical manufacturers time and money.

GE Healthcare has introduced KUBio™, an innovative off-the-shelf, modular factory designed to save manufacturers of biopharmaceuticals both time and money.

KUBio’s pre-made modules, which are assembled at a customer’s chosen site to make a fully functional ready-to-run bioprocessing facility, are significantly faster to install than constructing a traditional factory.

The modules are equipped with GE Healthcare’s world-class technologies for the start-to-finish manufacture of biopharmaceuticals.

Worldwide demand for biopharmaceuticals - such as antibodies for the treatment of cancer and rheumatoid arthritis, as well as the new generation of innovative vaccines - is increasing dramatically, driven by the global ageing population, rising obesity levels and the global effort to reduce the incidence of vaccine preventable diseases.

KUBio will help manufacturers to respond to local healthcare needs and bring these potentially life-saving treatments to market more quickly.

KUBio is a fully functional off-the-shelf bioprocessing facility specifically designed to meet cGMP requirements while optimizing manufacturing flexibility and productivity.

The 1200m2 facility is pre-fabricated and delivered with a complete ready-to-use production line, based on GE Healthcare’s Ready-to-Process™ single-use technologies.

With a total planning, delivery and construction time of 14 - 18 months, compared to the traditional 24 - 36 months, both time-to-market and level of capital investment are significantly reduced.

The first modular facilities to be introduced will be configured for the manufacture of monoclonal antibodies. GE Healthcare also plans to introduce modules for the manufacture of other biopharmaceuticals.

“KUBio is a totally new approach to the manufacture of biopharmaceuticals, bringing our customers a greatly simplified way to build their production capacity,” said Olivier Loeillot, General Manager of Enterprise Solutions, GE Healthcare Life Sciences.

Loeillot continued, “With KUBio our customers will be able to cut months off the typical construction time, and greatly streamline the whole construction process. We’re already seeing interest from a wide range of customers, from governments wanting to develop in-country manufacturing capability right through to pharmaceutical companies wanting to expand production capacity in new locations. KUBio is an industry game-changer that will help them do just that.”

The introduction of KUBio expands GE Healthcare’s broad offering of world-class tools, technologies and services for the biopharmaceutical manufacturing industry, allowing customers to benefit from a wide range of solutions that can be tailored to meet specific needs, from pilot to commercial scale.

GE Healthcare’s start-to-finish technologies and services include Fast Trak training, PAA cell culture media, ReadyToProcess single use technologies, specialist purification media and Xcellerex biomanufacturing systems.

KUBio aligns with GE’s healthymagination initiative which focuses on reducing cost, increasing access and improving quality in healthcare.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Healthcare Life Sciences and Promosome Sign Licensing Agreement
Innovative mammalian cell line development technologies that show promise for increasing manufacturing efficiency of vital biopharmaceuticals.
Tuesday, April 29, 2014
GE Acquires Strategic Assets from Thermo
GE to acquire cell culture media and sera, gene modulation and magnetic beads businesses.
Monday, January 06, 2014
iBio, Inc. and GE Healthcare Form New Global Alliance
Companies to commercialize plant-based technologies for biopharmaceutical and vaccine manufacture.
Thursday, December 27, 2012
GE Healthcare Expands Shanghai Fast Trak Training Center
Expansion adds IN Cell, Biacore and DeltaVision technologies for drug discovery and development.
Monday, September 24, 2012
GE Healthcare Offers Fast Trak Training in Singapore
Fast Trak training and education courses provide practical training in the latest technologies and strategies for bioprocessing.
Tuesday, June 05, 2012
Karolinska University Hospital and GE Healthcare Collaborate to Advance Technologies for Cell Therapy
Pioneering three-year study will investigate technology and workflow needs in a clinical setting.
Wednesday, May 23, 2012
GE Healthcare to acquire Xcellerex Inc.
Addition of high growth company builds integrated, start-to-finish industry offering, focused on lowering costs, increasing productivity and reducing time to market.
Thursday, March 08, 2012
GE Healthcare and Neste Jacobs Form Strategic Alliance
Alliance will help healthcare providers worldwide increase access to life-saving treatments.
Tuesday, January 03, 2012
GE Healthcare and M+W Group Form Strategic Alliance in Vaccines, Insulin and Biopharmaceuticals
Companies to help emerging nations develop their own manufacturing capabilities for essential biopharmaceuticals, reducing reliance on imports.
Wednesday, December 14, 2011
NIBRT and GE Healthcare Announce Biopharmaceutical Research Collaboration
Joint research project to drive new technologies for the development and functional analysis of therapeutic antibodies.
Tuesday, October 04, 2011
GE Healthcare Appoints Kieran Murphy as Life Sciences CEO, Successor to Peter Ehrenheim
On 1 April 2011, Kieran Murphy will be promoted to succeed current Life Sciences President and CEO Peter Ehrenheim who will retire from GE after a transition period on July 31 2011.
Tuesday, February 22, 2011
G-CON Manufacturing and GE Healthcare Announce Intent to Collaborate in Developing Next Generation Modular Bio-therapeutic Manufacturing Technology
G-Con Manufacturing, LLC and GE Healthcare announce their intention to collaborate on the development of a modular portable bio-process manufacturing solution for vaccines and therapeutics.
Friday, December 03, 2010
Scientific News
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Study Backs Flu Vaccinations for Elderly
Brown University researchers found vaccines well matched to the year’s flu strain significantly reduce deaths and hospitalizations compared to when the match is poor, suggesting that vaccination indeed makes a difference.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
Major Advance Toward More Effective, Long-Lasting Flu Vaccine
Collaboration shows vaccine candidate can produce powerful ‘broadly neutralizing antibodies’ in animal models.
Immune System: Help for Killer Cells
A study from the University of Bonn may show the way to more effective vaccines.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!